A Study to Evaluate AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS)

NCT ID: NCT03981536

Last Updated: 2020-10-27

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 18 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-10-10
• Study Completion Date: 2020-11-02

Brief Summary

Single ascending doses of AP-101 will be administered by intravenous (IV) infusion

Conditions

Amyotrophic Lateral Sclerosis

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

AP-101: Dose Level 1

Single dose of AP-101

Group Type: EXPERIMENTAL

AP-101

Intervention Type: DRUG

Administered by intravenous infusion (IV)

AP-101: Dose Level 2

Single dose of AP-101

Group Type: EXPERIMENTAL

AP-101

Intervention Type: DRUG

Administered by intravenous infusion (IV)

AP-101: Dose Level 3

Single dose of AP-101

Group Type: EXPERIMENTAL

AP-101

Intervention Type: DRUG

Administered by intravenous infusion (IV)

Interventions

AP-101

Administered by intravenous infusion (IV)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• All participants must adhere to contraception restrictions
• Female patients of non-childbearing potential due to:

1. Menopause: spontaneous amenorrhea for at least 12 months not induced by a medical conditions such as anorexia nervosa and not taking medications that induced the amenorrhea (e.g., oral contraceptives, hormones, gonadotropin releasing hormones, anti-estrogens, selective estrogen receptor modulators, or chemotherapy)

2. Surgical sterilization

• Have possible, probable, probable laboratory supported or definite and definite familial laboratory-supported ALS in accordance with the El-Escorial criteria
• Have familial or sporadic ALS.
• With onset of ALS symptoms, specifically onset of muscle weakness within past 48 months
• Have slow vital capacity (SVC) of (greater than or equal to) ≥60%
• If on riluzole, must be on a stable dose
• If on edaravone, must have completed 2 cycles and are expected to remain on the same dose throughout the study
• Able to provide informed consent. If the patient is not able to provide written consent due to aggravation of disease condition, written informed consent may be provided by a legally authorized representative
• Have venous access sufficient to allow for blood sampling
• Have clinical laboratory test results within normal reference range for the population or study site, or results with acceptable deviations that are judged to be not clinically significant

Exclusion Criteria

• Are currently enrolled in, or discontinued from, within the last 30 days, a clinical trial involving an investigational drug or device or off-label use of a drug or device, or any other type of medical research judged not to be scientifically or medically compatible with this study
• Have previously completed or withdrawn from this study
• Have a history or presence of medical illness including, but not limited to, any cognitive, cardiovascular, hepatic, hematological, renal, endocrine, or psychiatric, or any clinically significant laboratory abnormality that indicates a medical problem that would preclude study participation
• Show evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies
• Show evidence of hepatitis C and/or positive hepatitis C antibody
• Show evidence of hepatitis B and/or positive hepatitis B surface antigen
• Are women who are lactating.
• Have undergone a tracheostomy unless it was removed at least 6 months prior
• Are on feeding tube, unless the insertion of a feeding tube is considered prophylactic
• Are on nasal intermittent positive pressure ventilation (NIPPV) >4 hours per day or at the discretion of the medical monitor
• Have undergone stem cell therapy

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

AL-S Pharma

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Study Director

Role: STUDY_DIRECTOR

AL-S Pharma SA

Locations

London Health Sciences Centre, University Hospital

London, Ontario, Canada

Sunnybrook Health Sciences Centre, Toronto

Toronto, Ontario, Canada

Montreal Neurological Institute & Hospital

Montreal, Quebec, Canada

Countries

Canada

Other Identifiers

AP101-01

Identifier Type: -

Identifier Source: org_study_id